找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Cutaneous Melanoma and Precursor Lesions; Dirk J. Ruiter,Kees Welvaart,Soldano Ferrone Book 1984 Martinus Nijhoff Publishers, Dordrecht 19

[复制链接]
发表于 2025-3-30 11:04:12 | 显示全部楼层
Human Melanoma Associated Antigens Identified with Monoclonal Antibodies: Characterization and Potenigens referred to as melanoma associated antigens (MAA), have been identified with cell mediated immunity assays and with serological assays (for review, see 1,2). In the latter for many years the source of antibodies have been sera from patients with melanoma and sera from animals immunized with MA
发表于 2025-3-30 14:19:32 | 显示全部楼层
发表于 2025-3-30 19:20:43 | 显示全部楼层
Immune Responses to Human Malignant Melanomat tumors of this type may be immunogenic and may provoke immune responses in the tumor bearing host. Host control of tumor growth is best illustrated clinically by cases of spontaneous regression of tumors. Spontaneous regression is defined as the complete disappearance or the reduction in size of h
发表于 2025-3-31 00:31:05 | 显示全部楼层
发表于 2025-3-31 03:45:15 | 显示全部楼层
发表于 2025-3-31 07:40:12 | 显示全部楼层
Prognostic Factors for Cutaneous Melanomainical and histopathologic features of primary tumors. Observations of biologic behavior seem to be generalizable over wide geographic areas. For example, tumor behavior in Australia appears to be similar to that observed in the United States which in turn appears to be similar to that observed for
发表于 2025-3-31 11:02:48 | 显示全部楼层
发表于 2025-3-31 14:36:12 | 显示全部楼层
发表于 2025-3-31 18:26:53 | 显示全部楼层
Local Excision and Regional Perfusion in High-Risk Stage-I Malignant Melanoma of the Extremitiesases. In recent years studies by Clark et al. (7) and Breslow (4) have revealed several additional clinical and histologic characteristics of the primary tumor to which prognostic significance can be ascribed. Tumor size, depth of invasion, ulceration, vascular invasion, and lymphoid reaction along
发表于 2025-3-31 22:51:52 | 显示全部楼层
The Use of Chemotherapy in the Management of Patients with Malignant Melanoma response rates are between 20 and 30%. Most of the responding patients in these trials have partial remissions and often the difference between the mean survivals of responding and non-responding patients is 4 months at most. Even this difference may not indicate that there is a real benefit in ter
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-26 22:16
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表